18 results about "Trophoblast" patented technology

The present application belongs to the field of cell therapy and immunotherapy, and provides a genetically engineered human trophoblast, a preparation method and application thereof. The human trophoblast takes K562 cells as starting cells, and stably expresses membrane-bound interleukin 21, CD137 ligand and Delta-like ligand 1 after genetic engineering. The constructed K562 three-factor trophoblast can significantly improve the expansion efficiency, activation state and functional stability of NK cells and γδT cells. The synergistic mechanism includes enhancing the proliferation, cytotoxicity and stemness maintenance of NK cells and γδT cells through STAT3, NF-κB and Notch signaling pathways, respectively. The human trophoblast has the advantages of good expression stability, significant functional enhancement, and high activity after freezing and recovery.

This invention belongs to the medical field and provides a human trophoblastic stem cell line derived from complete hydatidiform mole and its applications. The human trophoblastic stem cell line, with accession number CGMCC No. C2024411, can be induced to differentiate into syncytiotrophoblast and extravillous trophoblast, mimicking the differentiation and developmental defects of the trophoblastic lineage in hydatidiform mole. It can be used as an in vitro research model for complete hydatidiform mole and has broad application prospects in drug target research and genetic studies.

The application relates to the field of biotechnology, in particular to application of CADM1 in preparation of a drug for gestational diabetes mellitus. The application comprises: using a detection reagent for detecting the expression level of CADM1 in preparation of a detection drug for gestational diabetes mellitus. The application is based on the previous research of the applicant that the expression level of CADM1 in the placental trophoblast of a gestational diabetes mellitus patient is reduced, and it is found in an in-vitro experiment that CADM1 can promote the proliferation, migration and invasion of the placental trophoblast cells, and by constructing an mRNA expression amount of CADM1 and a receiver operating characteristic curve of a subject of a GDM patient, it is indicated that the mRNA expression amount of CADM1 is related to the GDM patient, which indicates that CADM1 is related to the placental trophoblast of the gestational diabetes mellitus patient, and it is indicated that the detection of the gestational diabetes mellitus can be realized by detecting the detection reagent for detecting the expression level of CADM1.

The application provides a trophoblast organ-on-chip system for simulating a maternal-fetal interface of a systemic lupus erythematosus model based on an organ chip and a construction method thereof, the system taking an organ chip as a carrier and comprising three core parts of a trophoblast organ, an endometrial chip and an SLE disease model. The application completes separation culture and characterization of the trophoblast organ, multi-cell co-culture construction and characterization of the endometrial chip, and then constructs a pathological model, and the three parts cooperatively form a three-dimensional maternal-fetal interface. The system can clearly observe the dynamic process of the trophoblast organ invading the endometrial chip, can detect the continuous secretion of hCG and SLE-related inflammatory factors, and breaks through the defects of the prior art model, such as low authenticity, inability to dynamically observe, single detection dimension and lack of standardization, and has both physiological and pathological adhesion and experimental repeatability, can multi-dimensionally characterize the cell phenotype and function of the maternal-fetal interface, and provides an in-vitro research platform for the pathological mechanism research of the SLE pregnancy-related abnormal maternal-fetal interface.

FIELD: oncology.SUBSTANCE: used to treat malignant embryonic tumors. The method involves pharmacological inhibition of factors that support tumor growth. A progesterone receptor antagonist is administered and immunological activation of the body's response against progesterone-induced blocking factor (PIBF), placental growth factor (PIGF) and trophoblastic β 1-glycoprotein.EFFECT: increased treatment reliability due to a comprehensive and selective effect on the tumor, simultaneous influence on both the primary tumor site and metastases, a reduction in the likelihood of relapse due to the destruction of the tumor vascular network, and a reduction in the overall toxic load on the patient's body during treatment.7 cl, 1 tbl, 5 ex

The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

The present disclosure relates to the field of pharmaceutical preparations, dosage regimens, and administration of an antibody-drug conjugate (ADC). More specifically, the ADC is composed of an anti-trophoblast cell surface antigen 2 (TROP2) antibody connected via a linker to an anticancer agent, such as topoisomerase I inhibitor.

The application aims to provide an application of a biological agent in treating placental dysfunction, and belongs to the technical field of medicine.The biological agent is composed of siRNA for inhibiting expression of a LOC101929800 gene, a transcript sequence of the LOC101929800 gene is SEQ ID NO.1 in the sequence listing, and a sequence of the siRNA is SEQ ID NO.10 and SEQ ID NO.11 in the sequence listing.The application finds that the siRNA can reverse the decrease of the invasion ability of the trophoblast cells caused by hypoxia-reoxygenation to a certain extent by transfecting the siRNA in the cells under hypoxia-reoxygenation, and therefore the siRNA can be used for preparing the biological agent for treating placental injury.

The application belongs to the technical field of biological medicine, and particularly relates to application of beta cell protein in preparation of medicines for preventing and treating abortion. The application finds and proves for the first time that the application of beta cell protein (BTC) promotes invasion and tube formation of the extravillous trophoblast cell line-HTR8 cells, BTC has obvious rescue effect on embryo resorption in a mouse model of early-mid pregnancy abortion, and BTC increases placental weight and improves placental development when injected into the mouse model of early-mid pregnancy abortion, thereby indicating that BTC can have certain therapeutic effect on abortion, and thus has good practical application value.

Provided is a mammalian derived cell model which can be used in anti-aging drugs. The mammalian-derived extracembryonic trophoblast cell model is an early mammalian-derived extracembryonic stage. The change model of differentiation of cells into exoembryonic trophoblastic cells / organoids and the aging evaluation index system can be used various anti-aging research and target testing, anti-aging drug detection, screening, identification and innovative drugs / natural products Research and development of chemicals, and / or health foods and additives. It is helpful to screen and identify many resistances Candidate targets for aging can be further mechanized and functionally validated for future therapeutic use. The Screening of anti-aging drugs or natural products will produce huge economic and social benefits.

The application discloses application of a SUCNR1 gene expression inhibitor in preparation of a product for preventing or treating a dairy cow dystocia. The application provides application of a substance taking a SUCNR1 protein as an inhibition target and / or a substance taking a SUCNR1 gene as an inhibition target in preparation of a product. The application of the product is as follows: promoting trophoblast cell apoptosis; inhibiting macrophage M2 type polarization; promoting trophoblast cell apoptosis by inhibiting macrophage M2 type polarization. The inventors of the application find that silencing the SUCNR1 gene can inhibit a PI3K signal pathway, thereby inhibiting macrophage M2 type polarization, thereby promoting trophoblast cell apoptosis, thereby helping to solve the problem of dystocia.

This invention discloses an euploidy prediction method based on the fusion of blastocyst developmental dynamics and spherical harmonic decomposition. The method acquires multifocal plane image sequences of blastocysts using a time-difference imaging system and extracts dynamic parameters. After semantic segmentation and depth estimation, a three-dimensional surface model is obtained through surface reconstruction. The trophoblast cell instances are segmented to obtain three-dimensional centroid coordinates. These centroid coordinates are radially projected onto a unit sphere, and a spherical density function is constructed after excluding the inner cell mass mask. Spherical harmonic decomposition is then normalized using Monte Carlo zero-model normalization to obtain normalized power spectra at each degree. The basic morphological features, dynamic parameters, and spherical harmonic features are fused and filtered before training an ensemble learning model to output prediction results. This invention is the first to introduce spherical harmonic analysis into blastocyst assessment, capturing multi-scale spatial distribution information that global statistics cannot obtain. The power spectrum exhibits rotational invariance, and zero-model normalization eliminates cell number confounding.

This disclosure relates to conjugates, such as antibodies and their antigen-binding fragments, that are capable of binding to trophoblast cell surface antigen-2 (TROP2) in general. Similarly, this disclosure also discloses conjugates capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. A single-domain antibody that specifically binds to amino acid residues of the extracellular domain of TROP2 is provided.

First, a three-dimensional image (D2) of a blastocyst embryo is acquired by optical coherence tomography. Secondly, a parameter (P) representing at least one of a volume of an inner cell mass, a thickness of an inner cell mass, a thickness distribution of an inner cell mass, a volume of a trophectoderm, a thickness of a trophectoderm, a thickness distribution of a trophectoderm, or the number of cells in a trophectoderm is calculated on the basis of the three-dimensional image (D2). Then, the parameter (P) of a blastocyst embryo to be classified is input to a trained machine learning model (M1, M2, M3) that has the parameter (P) as an input variable and has a classification result of the blastocyst embryo as an output variable, and the blastocyst embryo is classified on the basis of a classification result output from the machine learning model. Thus, classification of the blastocyst embryo can be performed quantitatively on the basis of the three-dimensional image (D2).

The present invention provides a method for reprogramming a human somatic cell to a cell exhibiting at least one characteristic of a trophoblast stem cell (TSC), the method comprising the following steps in order: a) increasing the protein expression of one or more factors in the somatic cell, wherein the factors are for reprogramming the somatic cell towards a pluripotent state; b) culturing the cell for a sufficient time and under conditions to allow the reprogramming of the cell towards a pluripotent state; c) contacting the cell with a culture medium suitable for sustaining trophoblast stem cells (TSC); and d) culturing the cell in the TSC medium for a sufficient time and under conditions to allow the cell to exhibit at least one characteristic of a TSC, thereby reprogramming the somatic cell to a cell exhibiting at least one characteristic of a TSC.

The application belongs to the technical field of biotechnology, and particularly relates to a bTSCM culture medium and a method for obtaining trophoblast stem cells. The bTSCM culture medium comprises a basic culture medium and an additive component added in the basic culture medium; the additive component can synergistically regulate key signal pathways, epigenetic states and cell proliferation and survival, thereby inhibiting differentiation of non-trophoblast lineages, maintaining specific gene expression of trophoblast stem cells, keeping an undifferentiated state, and promoting establishment and stability of cell fate.

This invention relates to the use of baicalin in the preparation of drugs for treating and / or alleviating preeclampsia. The drugs are used to inhibit ferroptosis in placental trophoblasts and / or placental tissue, manifested by increasing the expression level of at least one of GPX4, SLC7A11, and FTH1, increasing GSH content and / or GPX activity, and decreasing Fe... 2+ It can reduce MDA, lipid ROS and / or mitochondrial ROS levels, and improve preeclampsia-related hypertension, proteinuria, placental oxidative stress and adverse pregnancy outcomes. This application can be used to prepare preeclampsia treatment and / or alleviation drugs with baicalin monomer as the active ingredient.

The application relates to a preparation method and application of sPL gel for endometrial injury repair, relates to the field of endometrial repair drugs, and aims at solving the problems of short treatment time and poor treatment effect of existing platelet-rich plasma. Method: 1. preparing a platelet lysate PL; 2. diluting placental chorionic trophoblast cells with complete culture medium to obtain a cell suspension, culturing the cell suspension by adding bisabolene, collecting a culture solution, filtering the culture solution to obtain a conditioned medium, and mixing the platelet lysate PL and the conditioned medium to prepare sPL; 3. adding a collagen solution and carbomer to the sPL, uniformly mixing the sPL, collagen solution and carbomer to prepare sPL gel. The sPL gel prepared by the method can be solidified by temperature rise, effectively improves the internal microenvironment of the uterine cavity, and is used for promoting the repair of endometrial injury.